Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial

• প্রধান লেখক: Deborah Watson-Jones, ProfPhD (লেখক), John Changalucha, MSc (লেখক), Hilary Whitworth, PhD (লেখক), Ligia Pinto, PhD (লেখক), Paul Mutani, MD (লেখক), Jackton Indangasi, MSc (লেখক), Troy Kemp, PhD (লেখক), Ramadhan Hashim, BSc (লেখক), Beatrice Kamala, Dip (লেখক), Rebecca Wiggins, PhD (লেখক), Twaib Songoro, BA (লেখক), Nicholas Connor, MSc (লেখক), Gladys Mbwanji, MSc (লেখক), Miquel A Pavon, PhD (লেখক), Brett Lowe, MSc (লেখক), Devis Mmbando, BSc (লেখক), Saidi Kapiga, ProfPhD (লেখক), Philippe Mayaud, ProfMD (লেখক), Silvia de SanJosé, MD (লেখক), Joakim Dillner, ProfPhD (লেখক), Richard J Hayes, ProfDSc (লেখক), Charles J Lacey, ProfMD (লেখক), Kathy Baisley, MSc (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2022-10-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Summary: Background: An estimated 15% of girls aged 9-14 years worldwide have been vaccinated against human papillomavirus (HPV) with the recommended two-dose or three-dose schedules. A one-dose HPV vaccine schedule would be simpler and cheaper to deliver. We report immunogenicity and safety results...